| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis |
Trial sites expanded: 20 -> 23 locations |
| 2026-07-29 | NCT07067463 A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis |
Trial sites expanded: 34 -> 40 locations |
| 2026-07-23 | NCT07067463 A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis |
Trial sites expanded: 27 -> 32 locations |
| 2026-07-19 | NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis |
Trial sites expanded: 13 -> 18 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Multiple Sclerosis (MS) Primary Progressive | Recruiting |
| NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Recruiting |
| NCT05786573 | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Warm Autoimmune Hemolytic Anemia | Active, Not Recruiting |
| NCT05662241 | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | IgG4 Related Disease | Active, Not Recruiting |
| Phase 2 | |||
| NCT06559163 | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Recruiting |
| NCT06564311 | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | Relapsing Multiple Sclerosis | Active, Not Recruiting |
| Phase 1 | |||
| NCT05638854 | A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and… | Healthy Volunteers | Recruiting |